
Urologic Oncologist @Moffittnews via @MoffittGuONC & @UrologyAlberta | šØš¦ | If you hang out at the barbershop long enough, youāll eventually get a haircut
Tampa, FL
Joined February 2020
- Tweets587
- Following1K
- Followers773
- Likes1.5K
Logan Zemp retweeted
Important change in the 2026 @AmerUrological NMIBC Guidelines: all high-grade Ta tumors are now classified as high-risk.
This reduces a long-standing source of heterogeneity in the intermediate-risk group and should improve risk-appropriate treatment for patients, while creating cleaner, more meaningful populations for clinical trials.
Great to see the evidence translate into practice. @IBCG_BladderCA @UrogerliMD @pjhensley11 @AmirHorowitz @mouwlab @spsutkaMD @shilpaonc @AndreaNecchi @LAUrology_NL @karima_oualla @PGrivasMDPhD @marigfern @SpiessPhilippe @UroCancerMD
Time to revisit something Iāve been saying for years: TaHG bladder cancer is not intermediate risk. The clinical outcomes, molecular biology ... all point in the same direction.
Yet some frameworks allow < 3cm TaHG tumors to be downgraded into āintermediate riskā alongside low-grade disease.
That classification has real consequences for patients:
⢠undertreatment
⢠less rigorous surveillance
⢠in some studies, these patients are even placed on observation as a supposedly appropriate ācontrol arm.ā
TaHG is high risk. š§µ @BladderCancerUS @WorldBladderCan @IBCG_BladderCA
Logan Zemp retweeted
Congrats to our Urologic Oncology matched fellows! We excited for you to join the Moffitt team!
It was a fantastic surgical simulation opportunity with @MoffittGUOnc fellows, faculty members and other specialists from @MoffittNews today. The skills we honed will undoubtedly make a huge difference in the lives of many future patients.
Logan Zemp retweeted
Many @MoffittGUOnc faculty helped shape my career. Truly an honor to be visiting professor & share my academic journey w/ fellows. Phenomenal program w/ amazing ppl! Thanks @LoganZemp @MichaelPochMD @WadeJSexton9 @SpiessPhilippe @JulioPowSangMD Alice Yu Brandon Manley @UrogerliMD
Logan Zemp retweeted
Outcomes from 1027 pc-RPLNDs in NSGCT:
⢠Residual mass size correlates with higher rates of teratoma and yolk sac tumor
⢠Primary tumor histology associated with RPLND pathology
š doi.org/10.1016/j.annonc.202ā¦
@RichMatulewicz @SpiessPhilippe @SpiessPhilippe @drgaganprakash @LuisMedinaMD @npaesa @CMercinelli @dramandeeparora @CurtisPettaway1 @MDAndersonNews @MoffittNews @TataMemorial @MUSC_UroOnc @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @orchidcancer @ERN_eUROGEN @EauPatient @JadChahoud
Day 1 on the new DV5 š¤ at @MoffittNews today. Overall, the ergonomics, integrated insufflation, and laparoscope are significant upgrades. The minor downsides, changes to the bovie and vessel sealer sounds, were tolerable. Another great day in paradise! @IntuitiveSurg
2
27
926
Logan Zemp retweeted
New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)
Full text: authors.elsevier.com/a/1mf5Cā¦
@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery
Logan Zemp retweeted
Exceptional meeting with close friends and thought leaders. All dedicated to advancing the fundamental knowledge and treatment standards of bladder cancer variant histologies. A huge unmet need. Thanks everyone for being part of this important effort.
Honored to present this morning at the joint IBCGāGSRGT Bladder Cancer Variant Histology Meeting in Tampa alongside Tom Flaig. We reviewed prior clinical trials in this space ā highlighting lessons in eligibility, accrual, pathologic QA, and endpointsāand discussed how these insights can shape smarter study designs moving forward. Variant histology bladder cancer ā one disease. š¬
@LoganZemp @SpiessPhilippe @UroDocAsh @GdGrass @Prem_Ramkumar @AndreaNecchi @UrogerliMD @SethlernerMD @shilpaonc @siadaneshmand @TomFlaigMD @MassGenBrigham @IBCG_BladderCA
#BladderCancer #CancerResearch #ClinicalTrials
Logan Zemp retweeted
Honored to present this morning at the joint IBCGāGSRGT Bladder Cancer Variant Histology Meeting in Tampa alongside Tom Flaig. We reviewed prior clinical trials in this space ā highlighting lessons in eligibility, accrual, pathologic QA, and endpointsāand discussed how these insights can shape smarter study designs moving forward. Variant histology bladder cancer ā one disease. š¬
@LoganZemp @SpiessPhilippe @UroDocAsh @GdGrass @Prem_Ramkumar @AndreaNecchi @UrogerliMD @SethlernerMD @shilpaonc @siadaneshmand @TomFlaigMD @MassGenBrigham @IBCG_BladderCA
#BladderCancer #CancerResearch #ClinicalTrials
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotināpembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
Logan Zemp retweeted
#RoboUroOnc @CityofHopeSurg #Urology fellow, Dr. Ahmad Saeed Imam, @ImamOfUrology, presenting multidisciplinary research efforts at #WSAUA25 @auawest in #prostatecancer & #ilealureter creation. @SalvadorjcMD @BYuhMD @WesleyYipMD @arafflemd @montypal @COHurol @ClaytonLauMD
Proud of our @USFUrology stars ā Dr. Joe Balbona, Dr. Alyssa Biollota & Dr. Tyler Cook ā finishing their @MoffittNews rotation! Until next time ā the future of urology is in great hands. š
@AmerUrological @UrologyMatch
Logan Zemp retweeted
šØPublication alert in @UrolOncol!
National complication and cost burden of transurethral resection of bladder tumor for bladder cancer
Click to read the articleā¶ļø bit.ly/3JmhHt7
Logan Zemp retweeted
š The @AmerUrological and the UCF are excited to recognize 12 researchers as recipients of the 2025 Urology Care Foundation Research Scholar Awards! This program has invested over $30 million to support over 675 Research Scholars!
Click to learn more š bit.ly/48G1Iyn
Logan Zemp retweeted
A very sad day learning that a giant in urology passed, Donald G. Skinner MD His impact was profound. His commitment to surgical excellence was only matched by his devotion to pt care and teaching. Simply the best mentor, colleague and friend
RIP Boss
@UroOnc @AmerUrological
Welcome to the @MoffittNews family! The future is bright! @SUO_YUO @UroOnc @AmerUrological @MUSC_Urology @Yale_Urology @GUUrology
Congrats @GabrielleYanke2 @BMoraGarijo , Dr. Syed Rahman on matching with Moffitt GU Onc. weāre super excited youāll be joining us next year!!
Logan Zemp retweeted
Couldnāt agree more. @LeileiXiaUro found similar results in updated cohort 2010-2018 cT1 + LVI compared to T2 w/o LVI associated with significantly worse OS HR 1.63. @PennUrology @tbivala1
LVI is tough. With our improved management and therapies I am generally aggressive in promoting bladder sparing for NMIBC - but this gives pause: T1 with LVI had higher node positivity rates than MIBC without LVI, at least in NCDB 2004-2014..
Need large granular series that include more variables (blue light, presence of LVI at re-TURBT) and contemporary agents (especially immune) to get more answers
pubmed.ncbi.nlm.nih.gov/3029ā¦
Logan Zemp retweeted
Bladder cancer session #JSMO25 - Longer term follow up for EVP showing 34 months median OS and 2 year median duration of response. Adverse events different from standard chemotherapy @uromigosjapan
Not only a great surgeon & the @SUO_YUO @MoffittGUOnc fellowship director, but an innovative researcher. Congrats on your TIL therapy trial Dr @michael_poch.
Urologist Michael Poch, MD (@Michael_Poch) shares insights on an innovative trial exploring TIL therapy for bladder cancer. This study is pushing boundaries and applying #TILtherapy to a new type of cancer.
Read more: bit.ly/3Xfq3pA
#CancerResearch







































